Vanda Pharmaceuticals Inc. (VNDA)

Over the past six months, Vanda Pharmaceuticals' stock price has been impacted by several key events. The FDA approval of NEREUS for the prevention of vomiting induced by motion led to a surge in VNDA shares. The New Drug Application for Bysanti for bipolar I disorder and schizophrenia was under review by the FDA with a PDUFA target action date of February 21, 2026. Vanda reported its Q4 and full-year 2025 financial results, showing a 9% increase in total revenues to $216.1 million for the full year, primarily driven by a 24% increase in Fanapt net product sales, but also reported a significant GAAP net loss of $220.5 million for FY25, partly due to a one-time, non-cash tax valuation allowance, which led to investor frustration and a stock decline. Vanda announced the initiation of Thetis Study, a clinical trial of NEREUS for the prevention of vomiting induced by GLP-1 receptor agonists. Vanda Pharmaceuticals publicly criticized an FDA legislative proposal for FY 2027 that would extend drug review timelines and eliminate formal evidentiary hearings. The stock price as of April 8, 2026, was $7.29 per share, representing a 76.51% increase over the past year and a 33.8% increase in the last six months, but was down 13.46% over the 30 days leading up to April 1, 2026.

The provided information does not explicitly detail demand seasonality for Vanda Pharmaceuticals' products and services. However, the nature of some of its products, such as HETLIOZ for sleep-wake disorders and NEREUS for motion sickness, could potentially have seasonal variations in demand, though this is not confirmed in the search results.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs. Its commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, Fanapt for schizophrenia and bipolar I disorder, PONVORY for relapsing forms of multiple sclerosis and inflammatory/autoimmune disorders, NEREUS for the prevention of vomiting induced by motion in adults, Bysanti for bipolar I disorder and schizophrenia, and Imsidolimab for Generalized Pustular Psoriasis. Vanda also has a pipeline of other drugs in development.

Vanda Pharmaceuticals is a global biopharmaceutical company headquartered in Washington, D.C., United States. The company sells its products predominantly in the United States, and also has a presence in Israel, Europe, and Canada. It maintains offices in the United Kingdom and Germany.

Vanda Pharmaceuticals has actively worked on enhancing its brand reputation and product awareness. The company launched a direct-to-consumer campaign in 2025, which contributed to meaningful gains in brand awareness for Fanapt and PONVORY. The FDA approval of NEREUS for motion sickness was a significant positive event. However, Vanda has also been involved in legal and regulatory challenges that could impact its reputation, including litigation against the FDA and criticism of the FDA's FY 2027 legislative proposal. The reported weak FY25 financial results also led to investor frustration, which could affect market perception.

Vanda Pharmaceuticals Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 26.63% to 71.01% of the company's stock is held by institutional investors, with major shareholders including BlackRock, Inc., Vanguard Group Inc, and Renaissance Technologies Llc. Insiders own approximately 8.34% to 10.45% of the stock. Public companies and individual investors collectively own about 12.66% to 52.36% of the company's stock.